ATE555783T1 - Mittel zur behandlung oder prävention von ischämischer neuropathie - Google Patents

Mittel zur behandlung oder prävention von ischämischer neuropathie

Info

Publication number
ATE555783T1
ATE555783T1 AT04799962T AT04799962T ATE555783T1 AT E555783 T1 ATE555783 T1 AT E555783T1 AT 04799962 T AT04799962 T AT 04799962T AT 04799962 T AT04799962 T AT 04799962T AT E555783 T1 ATE555783 T1 AT E555783T1
Authority
AT
Austria
Prior art keywords
agents
treating
preventing ischemic
ischemic neuropathy
independently hydrogen
Prior art date
Application number
AT04799962T
Other languages
English (en)
Inventor
Kazuhito Ikeda
Toru Kimura
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE555783T1 publication Critical patent/ATE555783T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04799962T 2003-12-05 2004-11-30 Mittel zur behandlung oder prävention von ischämischer neuropathie ATE555783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003406804 2003-12-05
PCT/JP2004/018114 WO2005053678A1 (ja) 2003-12-05 2004-11-30 虚血性神経障害治療又は予防剤

Publications (1)

Publication Number Publication Date
ATE555783T1 true ATE555783T1 (de) 2012-05-15

Family

ID=34650292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04799962T ATE555783T1 (de) 2003-12-05 2004-11-30 Mittel zur behandlung oder prävention von ischämischer neuropathie

Country Status (7)

Country Link
US (2) US20070105948A1 (de)
EP (1) EP1693060B1 (de)
JP (1) JP4820170B2 (de)
KR (1) KR20070029123A (de)
AT (1) ATE555783T1 (de)
ES (1) ES2382808T3 (de)
WO (1) WO2005053678A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025775A1 (en) * 2009-08-24 2011-03-03 Alterman Ron L Apparatus for trans-cerebral electrophoresis and methods of use thereof
WO2012018069A1 (ja) 2010-08-06 2012-02-09 大日本住友製薬株式会社 脊髄損傷治療用製剤
ES2577009T3 (es) 2011-02-25 2016-07-12 Keio University Agente terapéutico para daño del nervio sensorial corneal que contiene un inhibidor de semaforina como principio activo
CN108779090B (zh) 2016-01-15 2022-07-26 住友制药株式会社 2环性杂环化合物
JPWO2020122101A1 (ja) * 2018-12-12 2021-10-28 大日本住友製薬株式会社 新規投与方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506202A (ja) * 1991-03-22 1994-07-14 ゼノバ　リミテッド 医薬用キサントン誘導体
US5266580A (en) * 1992-01-24 1993-11-30 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol
JPH08165237A (ja) * 1994-12-12 1996-06-25 Bio Kosumosu:Kk 血液流動性改善剤
AU2001276694A1 (en) * 2000-07-28 2002-02-13 Sumitomo Pharmaceuticals Company, Limited Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient
JP4633897B2 (ja) * 2000-08-17 2011-02-16 長瀬産業株式会社 神経突起伸長剤
WO2003062440A1 (fr) * 2002-01-21 2003-07-31 Sumitomo Pharmaceuticals Co., Ltd. Derive de xanthone
EP1475382B1 (de) * 2002-01-24 2008-12-10 Dainippon Sumitomo Pharma Co., Ltd. Verbindungen als semaphorininhibitoren

Also Published As

Publication number Publication date
US20070105948A1 (en) 2007-05-10
EP1693060A4 (de) 2008-09-17
ES2382808T3 (es) 2012-06-13
US20110105599A1 (en) 2011-05-05
WO2005053678A1 (ja) 2005-06-16
JPWO2005053678A1 (ja) 2007-06-28
KR20070029123A (ko) 2007-03-13
EP1693060B1 (de) 2012-05-02
EP1693060A1 (de) 2006-08-23
JP4820170B2 (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
GB0225474D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
GB0318447D0 (en) Therapeutic agents
GB0223038D0 (en) Therapeutic compounds
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
CY1110901T1 (el) Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
GB0201508D0 (en) Organic compounds
DE60119784D1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
NO20064282L (no) Morfolinforbindelser
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MY147404A (en) Process for preparation of n-benzoyl-staurosporine
GB0207495D0 (en) Organic compounds
BRPI0416720B8 (pt) composto, processo para a preparação de um composto, composição fungicida e método de combate curativo ou preventivo dos fungos fitopatogênicos de culturas
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BRPI0410837A (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição
TW200602295A (en) Organic compounds
PL1744736T3 (pl) Sposób leczenia zespołu suchego oka i zapalenia błony naczyniowej oka